Hospital Sao Vicente de Paulo

Passo Fundo, Rio Grande do Sul 99010-090

1 studies enrolling now · 11 studies all time

What they study most

BRAF V600E-mutant Metastatic Colorectal Cancer, COVID-19, Colitis, Ulcerative, Community-acquired Pneumonia, Crohn Disease, Crohn's Disease, Diabetes Mellitus, Type 2, Influenza, Malignant Melanoma, Pneumonia, Rheumatoid Arthritis, Triple Negative Breast Neoplasms

Studies at this site

• AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia — Recruiting now
• Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 — Running, not enrolling
• A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer — Completed
• A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease — Completed
• Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 — Stopped early
• Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer — Completed
• Investigational Study of Delayed Release Metformin — Paused
• Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma — Completed
• Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) — Completed
• Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza — Completed
• Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) — Completed